A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies

Vincent Ribrag, L. Iglesias, Filippo de Braud, Brigette Ma, Tomoya Yokota, Thomas Zander, Anna Spreafico, Vivek Subbiah, Anna Lena Illert, Daniel Tan, Armando Santoro, Pamela N. Münster, Youko Suehiro, Yongsheng Wang, Dong-Mei Ji, Shuqi Chen, Karen Beltz, Naoko Suenaga, Thiruvamoor Ramkumar, Fangjun Luo, Clinton Lai, Zev A. Wainberg